At 10.4% CAGR, Europe Heart Transplant Market is Projected to be Worth US$ 8,789.67 Million by 2030, says Business Market Insights

According to Business Market Insights research, the Europe heart transplant market was valued at US$ 3,970.32 million in 2022 and is expected to reach US$ 8,789.67 million by 2030, registering a CAGR of 10.4% from 2022 to 2030. Increasing target disease incidence and growing geriatric population are among the critical factors attributed to the Europe heart transplant market expansion.

The geriatric population is prone to CVDs, orthopedic disorders, metabolic disorders, and neurological disorders, among others. According to the WHO, the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. As per European Commission's data, as of January 1, 2023, the estimated population of the European Union was 448.8 million, with almost one-fifth (21.3%) of the population being 65 years of age or older. The EU's population reached a median age of 44.5 years on January 1, 2023. This indicates that while half of the population of the EU was younger, the other half was older than 44.5 years. Hence, the growing elderly population, along with the increasing prevalence of heart failure, fuels the heart transplant market growth.

On the contrary, high cost of surgeries hampers the growth of Europe heart transplant market.

Based on surgery type, the Europe heart transplant market is bifurcated into orthotopic heart transplantation and heterotopic heart transplantation. The orthotopic heart segment held 78.4% share of Europe heart transplant market in 2022, amassing US$ 3,113.68 million. It is projected to garner US$ 7,001.02 million by 2030 to expand at 10.7% CAGR during 2022-2030.

In terms of type, the Europe heart transplant market is categorized into donor live heart, and artificial heart. The donor live heart segment held 73.6% share of Europe heart transplant market in 2022, amassing US$ 2,923.70 million. It is projected to garner US$ 6,361.02 million by 2030 to expand at 10.2% CAGR during 2022-2030. Further, artificial heart segment is categorized into ventricular assisted device and total artificial heart.

Based on end user, the Europe heart transplant market is segmented into hospitals, cardiac centers, and others. The hospitals segment held 59.4% share of Europe heart transplant market in 2022, amassing US$ 2,359.54 million. It is projected to garner US$ 5,344.60 million by 2030 to expand at 10.8% CAGR during 2022-2030.

By country, the Europe heart transplant market has been categorized into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Our regional analysis states that Germany captured 27.0% share of Europe heart transplant market in 2022. It was assessed at US$ 1,070.00 million in 2022 and is likely to hit US$ 2,481.33 million by 2030, exhibiting a CAGR of 11.1% during 2022-2030.

Key players operating in the Europe heart transplant market are Terumo Corp, Abbott Laboratories, SynCardia Systems LLC, BioVentrix Inc, Berlin Heart GmbH, LivaNova Plc, and Calon Cardio-Technology, among others.

• In June 2021, Abbott Laboratories announced that it has enhanced its capacity and supply for mechanical circulatory support (MCS) devices, Medtronic HeartWare ventricular assist device (HVAD). In addition, the company announced providing support training and education programs for its HeartMate 3 heart pump.
  
  
• In January 2020, Abbott Laboratories announced that the Food and Drug Administration (FDA) approved its HeartMate 3 left ventricular assist device (LVAD). LVAD is a minimally invasive surgical technique for the placement that avoids open surgery. In 2017, the FDA approved HeartMate 3 for bridge therapy for patients awaiting a heart transplant.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com